T2DM-Related Genetic Variants Predict All-Cause Mortality

This article originally appeared here.
Share this content:
T2DM-Related Genetic Variants Predict All-Cause Mortality
T2DM-Related Genetic Variants Predict All-Cause Mortality

FRIDAY, Feb. 19, 2016 (HealthDay News) -- Type 2 diabetes (T2D)-related genetic variants predict all-cause mortality, even after adjustment for body mass index (BMI), according to a study published online Feb. 16 in Diabetes Care.

Aaron Leong, M.D., from Massachusetts General Hospital in Boston, and colleagues examined the correlation between T2D-related genetic variants and mortality. Mortality risk was modeled using a genetic risk score (GRS) from a weighted sum of risk alleles at 38 T2D-related single nucleotide polymorphisms. The correlation with mortality was assessed in 6,501 participants, in age-, sex-, and BMI-adjusted models.

The researchers found that 1,556 participants died over 17 years. GRS correlated with mortality risk (odds ratio, 1.04 per T2D-associated risk allele; P = 0.05). GRS correlated positively with mortality risk in non-Hispanic white and non-Hispanic black populations, but not in Mexican-Americans. The negative trend in Mexican-Americans was primarily due to those with BMI <25 mg/m². The positive association in non-Hispanic whites was strongest among those with BMI ≥30 kg/m².

"In the United States, a higher T2D genetic risk was associated with increased mortality risk, especially among obese non-Hispanic whites," the authors write. "The underlying genetic basis for mortality likely involves complex interactions with factors related to ethnicity, T2D, and body weight."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths